Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis (original) (raw)
Related papers
Annals of Tropical Medicine and Public Health, 2020
This study is done to compare safety and efficacy of antiinflammatory activity of 1% prednisolone acetate eye drops vs 0.05% difluprednate eye drops vs 0.5% loteprednol etobanate eye drops following u ncomplicated cataract surgery. The patients distributed across the three groups were comparable in terms of age, sex and grade of nuclear sclerosis. The difference in the proportion of ocular pain and anterior chamber inflammatory markers (aqueous cells and aqueous flare) on day 1 and day 7 across post-operative drugs used was statistically not significant. The mean difference in IOP, mean macular thickness and mean Log Mar visual acuity on Day 1,7,14 and 28 across post-operative drugs used was not statistically significant. All three drugs were comparable in terms of the ocular pain, Corneal clarity, IOP, anterior chamber activity, macular thickness & visual acuity. In view of less frequent dosing, better patient compliance, reduced total steroid exposure combined with similar anti-inflammatory effect clinically when compared with prednisolone, it is concluded that soft steroids (loteprednol and difluprednate) can be used safely in the post-operative regimen of uncomplicated cataract surgery.
Difluprednate for the prevention of ocular inflammation postsurgery: an update
Clinical Ophthalmology, 2011
To review the most recent published data regarding the novel potent steroid, difluprednate ophthalmic emulsion, 0.05%. Methods: A comprehensive search of recent published literature including difluprednate was performed. Clinical studies relevant to the characteristics and clinical efficacy of difluprednate in controlling postoperative inflammation were included, and a synopsis of each study was developed. Results: Several recent publications were identified in which difluprednate was shown to be efficacious in the treatment of postoperative inflammation in different clinical settings, including a novel perioperative regimen. Additional literature retrieved from this search included data on the relative potency of difluprednate, potential utility in the posterior segment, as well as the advantages of the emulsion formulation. Conclusion: Difluprednate has been studied extensively and shown in recent literature to be a safe and effective topical anti-inflammatory drug. The proven strength and unique formulation of difluprednate, along with its potent efficacy in treating and preventing inflammation, provides clinicians with a beneficial treatment option.
Journal of Clinical & Experimental Ophthalmology, 2011
conducted at a single center, private, teaching, multi-specialty practice in Las Vegas, Nevada. The study began on 3 May 2010 and ended on 17 September 2010. There were a total of 137 eyes (patients) enrolled with 111completing the study. Medications were provided for all the patients throughout the study period and none of the patients in study incurred any cost relating to medications in the post-operative period. Patient selection and treatment group Patients with visually significant cataract that have consented to cataract surgery were informed of the study. Consenting subjects were enrolled and randomized into three groups: Control (steroid-[Gatifloxacin 0.3% {Allergan Inc.
US Ophthalmic Review, 2011
Purpose:To determine whether bromfenac as a single agent is just as safe and effective as a corticosteroid in post-operative cataract surgery.Methods:Retrospective chart review compared over 400 eyes undergoing cataract surgery. Two hundred eyes were analyzed in each group. The first group received topical Pred Forte® 1 % (prednisolone acetate 1 %, Allergan) four times daily for two weeks, then tapered over the following three weeks, and the second group had topical Bromday™ (bromfenac 0.09 %, ISTA) as a single agent once daily, two days before surgery and for four weeks after. Outcomes measured were best corrected visual acuity (BCVA), post-operative pain, inflammation, cystoid macular edema (CME), and raised intraocular pressure (IOP).Results:Both groups had excellent vision improvement, to 20/27.2 (Pred Forte group) and 20/26.6 (Bromday group) average BCVA at one month post-operation. Both groups had excellent pain and inflammatory control at the one-day, two-week, and one-month ...
Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery
Eye & Contact Lens: Science & Clinical Practice, 2017
To compare the outcomes and complications of topical difluprednate 0.05% and loteprednol gel 0.5% after routine cataract surgery. Methods: Subjects received either difluprednate emulsion 0.05% (n¼30 eyes) or loteprednol gel 0.5% (n¼30 eyes) after routine cataract surgery. Topical steroid drops were initiated 3 days before cataract surgery and continued for 2 weeks postoperatively. Anterior chamber (AC) cell grade, corneal edema, corneal pachymetry, visual acuity, ocular surface quality (Oxford scale), and intraocular pressure (IOP) were evaluated at 1 day, 1 week, and 1 month postoperatively. Results: Patients treated with difluprednate or loteprednol had statistically similar resolution of their AC cell grade and corneal edema at 1 day, 1 week, and 1 month postoperatively (P.0.05 at each study visit). Difluprednate-treated and loteprednol-treated eyes achieved a mean bestcorrected visual acuity of at least 20/25 by 1 week postoperatively (0.055 and 0.061 logarithm of the minimum angle of resolution, respectively; P¼0.82). The nasal ocular surface quality at 1 week had improved in loteprednol-treated eyes compared with difluprednate-treated eyes (1.0 vs. 1.9 Oxford score, respectively; P,0.001), but similar at all other visits. There was no statistical difference between IOP levels between both treatment groups (P.0.05). In the difluprednate-treated group, one patient developed rebound inflammation and two patients developed cystoid macular edema at their 1-month postoperative visit. Conclusions: The anti-inflammatory effect, visual recovery, and IOP of patients using topical difluprednate or loteprednol gel after cataract surgery are equivalent. There may be an additional short-term benefit of loteprednol gel in protecting the ocular surface after cataract surgery.
IP Innovative Publication Pvt. Ltd., 2018
Introduction: Post-operative ocular inflammation is a common occurrence following cataract surgery. Corticosteroids have been used to treat ocular inflammation; however, they carry a risk of side effects, particularly an increase in intra ocular pressure (IOP). Previous studies have proved that difluprednate is more efficacious compared to dexamethasone. Hence this study was undertaken to compare the efficacy of difluprednate ophthalmic emulsion 0.05% and dexamethasone 0.1% in postoperative management after small incision cataract surgery. Materials and Methods: A total 200 patients were selected as per inclusion criteria and equally divided between difluprednate and dexamethasone groups. Dexamethasone 0.1% or difluprednate0.05% was prescribed post operatively following small incision cataract surgery. Patients were examined on post-operative day 1, 7, 15 and 30 for anterior segment by slit-lamp examination and side effects. IOP was measured in both the groups on day 30. Results: In our observation both drugs were efficient in the reduction of anterior chamber cells and flare with difluprednate being more rapid. Corneal edema was reduced equally by both the drugs at all observation periods. There was no clinically significant IOP elevation in both difluprednate and dexamethsone group. Difluprednate was found to be more effective in controlling pain compared to dexamethasone. Conclusion: As per present study both difluprednate ophthalmic emulsion 0.05% eye drops and dexamethasone 0.1% eye drops were equally effective in reducing post cataract surgery inflammation. Hence, difluprednate emulsion 0.05% can be used in postoperative management after cataract surgery; nonetheless, further clinical trials with long follow- up period are required. Keywords: Cataract surgery, Dexamethasone, Difluprednate, Dose uniformity, Ocular inflammation, Opthalmic emulsion.
BMJ Open Ophthalmology, 2021
AimsTo investigate changes in the prescribing patterns of postoperative eye drops following cataract surgery in Sweden from 2010 to 2017.MethodsData from cataract procedures registered in the National Cataract Register during the month of March from 2010 to 2017 were record linked and sent to the Swedish Prescribed Drug Register, which allowed us to determine which eye drops the patients had obtained from 3 months presurgery to 2 weeks post surgery.ResultsDuring the 8-year study period, 54 889 surgeries were registered. Combination treatment with steroid and non-steroidal anti-inflammatory drug (NSAID) eye drops increased from 12% in 2010 to 60% in 2017 (p<0.001) while monotherapy with steroids decreased from 71% in 2010 to 26% in 2017 (p<0.001). Monotherapy with NSAIDs after surgery was fairly stable, at 17% in 2010 and 13% in 2017 (p<0.001). Combination treatment was more frequent in patients with diabetic retinopathy (p<0.001) or age-related macular degeneration (p<...
Innovative Publiction
Aim: Comparison of topical Bromfenac versus topical Prednisolone acetate to control post cataract surgery ocular inflammation. Materials and Methods: Effectiveness and safety of topical Bromfenac(0.09%) and topical Prednisolone acetate (1%) was evaluated in patients of cataract surgery in controlling inflammation. Two groups of patients each having 100 patients were enrolled in this study. Both the groups were comparable in baseline parameters. Patients in each group were followed for one month after cataract surgery. Visual acuity, post-operative inflammation was evaluated by detailed slit-lamp examination in both groups at first day, one week and one month after the surgery. Results: The two groups had no statistically significant difference in post-operative inflammation and were well tolerated. Conclusion: Bromfenac(0.09%) is an effective drug in controlling ocular inflammation after uncomplicated cataract surgery having effect comparable to topical Prednisolone acetate(1%) with minimal side effects.